Novel population‐based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed
Thai P. Hong, Paul Gow, Michael Fink, Anouk Dev, Stuart Roberts, Amanda Nicoll, John Lubel, Ian Kronborg, Niranjan Arachchi, Marno Ryan, William Kemp, Virginia Knight, Helen Farrugia, Vicky Thursfield, Paul Desmond, Alexander J. Thompson, Sally Bell – 5 October 2015 – Hepatocellular carcinoma (HCC) incidence is rising rapidly in many developed countries.
Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis
Tatiana Hildebrand, Nadine Pannicke, Alexander Dechene, Daniel N. Gotthardt, Gabriele Kirchner, Florian P. Reiter, Martina Sterneck, Kerstin Herzer, Henrike Lenzen, Christian Rupp, Hannelore Barg‐Hock, Philipp Leuw, Andreas Teufel, Vincent Zimmer, Frank Lammert, Christoph Sarrazin, Ulrich Spengler, Christian Rust, Michael P. Manns, Christian P. Strassburg, Christoph Schramm, Tobias J.
Hypomethylation and hypohydroxymethylation of DNA in hepatocellular carcinoma and cholangiocarcinoma
Zhi Li, Jiexiong Feng, Xiaoyi Sun – 5 October 2015
Novel strategy to decrease reperfusion injuries and improve function of cold‐preserved livers using normothermic ex vivo liver perfusion machine
Babak Banan, Zhenyu Xiao, Rao Watson, Min Xu, Jianluo Jia, Gundumi A. Upadhya, Thalachallour Mohanakumar, Yiing Lin, William Chapman – 5 October 2015 – Normothermic extracorporeal liver perfusion (NELP) can decrease ischemia/reperfusion injury to the greatest degree when cold ischemia time is minimized. Warm perfusion of cold‐stored livers results in hepatocellular damage, sinusoidal endothelial cell (SEC) dysfunction, and Kupffer cell activation. However, the logistics of organ procurement mandates a period of cold preservation before NELP.
Paritaprevir/ritonavir, ombitasvir, and dasabuvir for treatment of recurrent hepatitis C virus infection in the human immunodeficiency virus coinfected liver transplant recipient
Salvatore Sollima, Laura Milazzo, Alessandro Torre, Elisa Calvi, Enrico Regalia, Spinello Antinori – 5 October 2015
Changes in liver acceptance patterns after implementation of Share 35
Kenneth Washburn, Ann Harper, Timothy Baker, Erick Edwards – 5 October 2015 – The Share 35 policy was implemented June 2013. We sought to evaluate liver offer acceptance patterns of centers under this policy. We compared three 1‐year eras (1, 2, and 3) before and 1 era (4) after the implementation date of the Share 35 policy (June 18, 2013). We evaluated all offers for liver‐only recipients including only those offers for livers that were ultimately transplanted. Logistic regression was used to develop a liver acceptance model.
Late‐onset arterial hemorrhage mimicking pseudoaneurysm after living donor liver transplantation
Teruyuki Miyazaki, Shintaro Yamazaki, Tadatoshi Takayama, Masamichi Moriguchi, Tokio Higaki, Tsutomu Kashimura, Hiroaki Nakazawa, Shyunichi Matsuoka, Mitsuhiko Moriyama, Masatoshi Makuuchi – 5 October 2015
Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation
Ian A. Rowe, Damien C. Tully, Matthew J. Armstrong, Richard Parker, Kathy Guo, Darren Barton, Gene D. Morse, Charles S. Venuto, Colin B. Ogilvie, Ditte L. Hedegaard, Jeffrey F. McKelvy, Flossie Wong‐Staal, Todd M. Allen, Peter Balfe, Jane A. McKeating, David J. Mutimer – 5 October 2015 – Hepatitis C virus (HCV) entry inhibitors have been hypothesized to prevent infection of the liver after transplantation. ITX5061 is a scavenger receptor class B type I antagonist that blocks HCV entry and infection in vitro.
Reply
Itxarone Bilbao, Magda Guilera – 5 October 2015